Uma Ramaswami

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

Joseph Muenzer, J. E. Wraith, Michael Beck et al. · Genetics in Medicine · 2006 · 585 citations · Full text

Life Sciences, Biochemistry, Enzymology +10

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

Marieke Biegstraaten, Reynir Arngrı́msson, Frédéric Barbey et al. · Orphanet Journal of Rare Diseases · 2015 · 345 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +13

Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey

Uma Ramaswami, Catharina Whybra, Guillem Pintos‐Morell et al. · Acta Paediatrica · 2005 · 258 citations

Life Sciences, Biochemistry, Pediatrics +13

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

Joseph Muenzer, Michael Beck, Christine M. Eng et al. · Genetics in Medicine · 2010 · 232 citations · Full text

Life Sciences, Biochemistry, Enzymology +1

Fabry disease: overall effects of agalsidase alfa treatment

Michael Beck, Riccardo Ricci, U. Widmer et al. · European Journal of Clinical Investigation · 2004 · 224 citations

Life Sciences, Biochemistry, Pharmacotherapy +11